Related Experiment Video
Updated: Apr 15, 2026
Stimulation of Vascular Endothelial Cells Using Neutrophil Extracellular Traps in the Presence of Low-Density Lipoprotein
Published on: August 12, 2025
Did we IMPROVE-IT: thoughts on LDL targeting post-trial?
1University of Glasgow, Institute of Cardiovascular and Medical Sciences, Clinical Research Facility, Tennent Building, Western Infirmary, Church Street, Glasgow, G12, UK.
Insights
The IMPROVE-IT trial shows adding ezetimibe to simvastatin significantly reduces cardiovascular events in acute coronary syndrome patients. Lowering LDL cholesterol with this combination therapy provides long-term benefits.
Area of Science:
- Cardiovascular Medicine
- Clinical Trials
- Pharmacology
Background:
- The IMPROVE-IT trial investigated the long-term effects of adding ezetimibe to simvastatin.
- Acute coronary syndrome (ACS) patients are at high risk for recurrent cardiovascular events.
- Understanding the role of cholesterol-lowering agents beyond statins is crucial.
Abstract:
Interview with Professor Chris Packard, MD, PhD by Tanya Stezhka (Commissioning Editor) The IMPROVE-IT trial, launched 9 years ago, has finally provided physicians with long-term efficacy and safety evidence for ezetimibe. The large-scale study in acute-coronary-syndrome patients showed a clear benefit in reducing cardiovascular events when added to simvastatin in this population. The size of the benefit was proportionate to the reduction in LDL cholesterol. We spoke to Professor Chris Packard (University of Glasgow, UK) about his interest in the trial, and the importance of lowering LDL and research in the wider clinical context.
More Related Videos
Related Concept Videos
01:20Lipid-Lowering Drugs: Statins and Miscellaneous Agents
01:26Atherosclerosis III: Management